Wednesday, July 8, 2026

pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR

ME Therapeutics

ME Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker MRKR. Primary therapeutic focus areas include Colorectal Cancer Screening, Screening for Colon Cancer, Platinum Sens

Vancouver, British Columbia, CA HQ
2018 Founded
4 Employees
Public company Type
MRKR · NYSE Ticker
Company details
Status
Public
HQ
Vancouver, British Columbia, CA
Founded
2018
Employees
4
Programs
13
Drugs
10
Patents
27
Clinical program

blood sampling

Unknown · other · Screening for Colon Cancer

blood sampling for Screening for Colon Cancer is a Unknown program (other) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).

Internal code AMD-CCR-2024-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Marker Therapeutics
Phase
Unknown
Modality
other
Indication
Screening for Colon Cancer
Status
active
Trials
1